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Abstract
Background: Orofacial granulomatosis [OFG] is a rare syndrome that may be associated with 
Crohn’s disease [CD]. We aimed to characterise this relationship and the management options in 
the biologic era.
Methods: This multicentre case series was supported by the European Crohn’s and Colitis 
Organisation [ECCO], and performed as part of the Collaborative Network of Exceptionally Rare 
case reports [CONFER] project. Clinical data were recorded in a standardised collection form.
Results: This report includes 28 patients with OFG associated with CD: 14 males (mean age of 
32  years, ±12.4 standard deviation [SD]) and 14 females [40.3  years, ±21.0 SD]. Non-oral upper 
gastrointestinal tract involvement was seen in six cases and perianal disease in 11. The diagnosis of 
OFG was made before CD diagnosis in two patients, concurrently in eight, and after CD diagnosis in 
18. The distribution of OFG involved the lips in 16 cases and buccal mucosa in 18. Pain was present in 
25 cases, with impaired swallowing or speaking in six. Remission was achieved in 23 patients, notably 
with the use of anti-tumour necrosis factors [TNFs] in nine patients, vedolizumab in one, ustekinumab 
in one, and thalidomide in two. A further five cases were resistant to therapies including anti-TNFs.
Conclusions: OFG associated with CD may occur before, concurrently with, or after the 
diagnosis of CD. Perianal and upper gastrointestinal [UGI] disease are common associations 
and there is a significant symptom burden in many. Remission can be obtained with a variety of 
immunosuppressive treatments, including several biologics approved for CD.
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1.  Introduction
Inflammatory bowel diseases [IBD], including ulcerative colitis and 
Crohn’s disease [CD], are characterised by chronic relapsing in-
flammation of the intestines. They are commonly associated with 
extra-intestinal manifestations [EIMs], with approximately a third 
developing an EIM in their disease course.1 Although the oral cavity 
is a common extra-intestinal site of involvement in IBD, orofacial 
granulomatosis [OFG] is rare in CD.
OFG was first described by Wiesenfeld et al. in 1985 and is in-
creasingly recognised.2 It is characterised by persistent or recurrent 
enlargement of the tissues of the orofacial area, secondary to an 
underlying non-caseating granulomatous inflammatory process. The 
most frequent sites of involvement are the lips, followed by oral ul-
cers, hyperplastic gingivitis, and buccal mucosal swelling.3,4 It should 
be noted that biopsy specimens of characteristic lesions may not al-
ways reveal granulomas on histology.5
OFG is considered by some to be a distinct entity, a condition 
without an identified systemic cause.6 Others, including this report, 
use it as a descriptive term to identify the collection of features due 
to a granulomatous process which may have an identifiable asso-
ciated condition, such as CD or sarcoidosis.5 The relationship be-
tween OFG and CD is unclear. Concurrent intestinal CD has been 
described in 20–50% of adult patients with OFG.7 However, many 
patients with OFG will have no intestinal disease, and others may 
have evidence of intestinal disease that is asymptomatic. Sanderson 
et al. found that endoscopic and histological intestinal abnormalities 
occurred in up to 60% of patients with OFG and without gastro-
intestinal symptoms.8 Although there are obvious similarities in the 
orofacial manifestations and histopathology of the two conditions, 
the human leukocyte antigen [HLA] profiles of idiopathic OFG 
may be different from those in Crohn’s disease. A  small study of 
16 patients with idiopathic OFG showed possible consistent HLA 
genotypes; in particular, HLA-A2 was seen in 50% but carries a 
comparative risk of CD of only 1.25, whereas HLA-A11 was seen 
in 25% and has an inverse association with CD.9 More recently, an 
analysis of NOD-2 variants has shown association with OFG associ-
ated with CD [OFG + CD] but not OFG alone.10 The inflammatory 
infiltrate also appears divergent, with patients with OFG only having 
a higher number of CD3-expressing T cells and CD11c-expressing 
dendritic cells in the connective tissues.11 Campbell et al. studied the 
clinical features between the two entities, and found that compared 
with OFG only, OFG + CD was more likely to have buccal sulcus in-
volvement, oral ulceration, raised C-reactive protein, and abnormal 
full blood count.4 The clinical response to azathioprine [AZA] also 
appears to be different, with one study including 60 OFG patients 
treated with AZA showing response to AZA at 12 months of 23.6% 
[n = 8/38] in OFG only cases versus 59.1% [n = 13/22] of cases of 
OFG + CD.12 In another study with 14 patients [seven with OFG 
only and seven with OFG + CD] treated with infliximab [IFX], the 
presence of intestinal CD did not predict response to IFX.13
There are few case series describing OFG + CD. This case series 
aims to further characterise this relationship and the management 
options in the biologic era. This is important, as OFG can be difficult 
to treat, with systemic steroids reported to provide remission in only 
half of patients, and carries a high psychological morbidity.6
2.  Methods
2.1.  Study design
The European Crohn’s and Colitis Organisation [ECCO] CONFER 
[COllaborative Network For Exceptionally Rare case reports] 
projects are based on an initiative introduced by ECCO to support 
individual investigators in identifying, assembling, and reporting 
together rare IBD cases of clinical relevance, which are otherwise 
seldom reported. The core of CONFER methodology is selecting 
certain topics worthy of investigation out of case proposals sub-
mitted by physicians involved with IBD. The Steering Committee 
makes an initial selection, identifying those cases with the highest 
scientific interest and proximity to the purpose of CONFER project. 
A Feasibility Network, comprising 30–35 high-volume IBD centres 
around the globe, is asked to identify similar cases, and the final deci-
sion is again taken by the Steering Committee based on the outcome 
of networking. This topic then becomes a CONFER project. ECCO 
supports dissemination of a call to identify similar cases encountered 
by IBD physicians worldwide using several tools: announcements in 
the ECCO Annual Congress and in national and international IBD 
meetings across Europe; emailing to all ECCO members; posting in 
ECCO website and ECCO eNews; flyers; and personal communi-
cation between ECCO members. Physicians are then prompted to 
report their case[s] using a predetermined standardised case report 
form. The call for the present case series was entitled ‘Orofacial 
granulomatosis associated with Crohn’s disease’. No financial sup-
port or input into the collection or analysis or publication of the data 
collected is provided by ECCO. ECCO and/or any of its staff mem-
bers may not be held liable for any information published in good 
faith in the ECCO CONFER articles.
2.2.  Patients and procedures
Patients with a diagnosis of OFG either before, concurrently with, or 
after IBD diagnosis were eligible for inclusion in this study. Diagnosis 
of OFG was made clinically by oral medicine or dermatology spe-
cialists, with the support of histology in half of the cases. Diagnosis 
of Crohn’s disease was made by gastroenterology specialists. Data 
were collected using a case report form, which was divided into two 
main sections. Section 1 included demographics, Montreal classifica-
tion, and previous medication. Section 2 included time of diagnosis 
of OFG, location and associated symptoms of OFG, and treatments 
and outcomes for the OFG. Data were collected and analysed an-
onymously, and handled according to local regulations. Informed 
consent was obtained where obligatory.
2.3.  Statistical analysis
All statistical analyses [frequencies, descriptive statistics] were done 
using a Microsoft® Excel® spreadsheet.
3.  Results
This report includes 28 patients with OFG + CD from nine dif-
ferent centres; 14 males with mean age of 32 years (±12.4 standard 
deviation [SD], range 14–60) and 14 females with mean age of 
40.3 years [±21.0 SD, range 11–79]. Baseline characteristics are de-
scribed in Table 1, and Table 2 gives details of OFG manifestations 
and outcomes. Figure 1 includes images related to one of the patients 
in this series.
Only six cases had a smoking history, 19 had never smoked, 
and a further three were undocumented. Very few had systemic 
conditions [diabetes mellitus in one case, coeliac disease in two, 
Hermansky‐Pudlak syndrome in one] or a positive family history 
of IBD [five cases]. CD location was ileal in six cases, colonic in 
six, and ileocolonic in 15. Upper gastrointestinal tract [UGI] dis-
ease occurred in six patients, with one of them having isolated UGI 
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[six cases of peripheral arthropathy including two also having ery-
thema nodosum, one of ankylosing spondylitis, and one of anterior 
uveitis]. CD phenotype was inflammatory in 16 cases, stricturing in 
seven, and penetrating in five. Eight patients had undergone intes-
tinal resection [ileal resection in one case, ileocaecal resection in two, 
hemicolectomy in two, proctocolectomy in two, and anterior resec-
tion in one].
Only half of the patients [14 patients] had a biopsy, and in two 
of these patients, granulomas were not present on histology. In the 
rest of the group, OFG was diagnosed clinically. OFG was diag-
nosed prior to CD in two cases [12 and 24  months beforehand], 
concurrently [within 12  months] with CD in eight, and after CD 
diagnosis in 18 [mean of 11.4  years after, range 12‐396 months]. 
For the 26 patients with CD diagnosed before or concurrently with 
OFG, luminal activity was quiescent in 13 patients and active in 13, 
as judged by the treating physician. C-reactive protein [CRP] was 
elevated in 14 cases, although 10 of these also had active luminal 
disease, and 10 cases had a normal CRP. Ten patients were treated 
with an anti-tumour necrosis factor [TNF] agent [with or without 
immunomodulator combination] and five with azathioprine mono-
therapy before or at diagnosis of OFG. Figure 2 shows the distri-
bution of OFG in the patients in this series. In addition, pain was 
present in 25 cases, with impaired swallowing or speaking in six.
A number of different treatments led to remission, based on clin-
ical assessment. The most common of these were therapies that in-
cluded an anti-TNF alpha [infliximab and adalimumab] [n = 9]; of 
these, six patients started anti-TNF alpha specifically to treat OFG 
and three started due to luminal disease. Vedolizumab [VDZ, n = 1], 
ustekinumab [UST, n = 1], and thalidomide [n = 2] were also used as 
successful rescue therapies, and were all started specifically to treat 
OFG. In particular, one patient initially responded to ciclosporin, but 
this had to be stopped due to side effects; remission was restored and 
maintained with thalidomide for at least 11 years. Another patient 
had no response to infliximab [IFX] but gained remission with thal-
idomide, although this subsequently had to stop due to side effects. 
Another patient achieved remission with adalimumab but had to 
discontinue due to side effects; this resulted in treatment with VDZ, 
which restored and maintained remission over a 5-year follow-up. 
Finally, another patient lost response to IFX, exhibited primary non-
response to VDZ, and achieved remission with UST. Recurrence 
occurred in five patients [including those described above]: after 
anti-TNF stopped in three cases; and mild breakthrough symptoms 
on anti-TNF in two cases. Remission was also achieved with topical-
only therapies in four patients [defaztan gel in one case, topical 
sodium tetraborate in two, hydrocortisone lozenges and antiseptic 
mouthwashes in one], local corticosteroid injections [triamcinolone] 
in two, and exclusive enteral nutrition [EEN] in one.
A further five cases were resistant to anti-TNF based therapies 
[three of whom were already on anti-TNF at the onset of OFG], 
assessed by unchanged OFG signs and symptoms. Of these, CD 
distribution was ileocolonic in three cases and colonic in two; 
perianal disease was present in two cases and none of these had an-
other EIM. All five cases had quiescent luminal disease. Three of 
Table 1. Demographic and disease characteristics of patients at 
baseline.
N %
Demographics Males [mean age 32 yr] 14 50.0
Females [mean age 40.3 yr] 14 50.0
Comorbidities Systemic comorbidities 4 14.3
Family history 5 17.9
Smoking history Current or former 6 21.4
Never 19 67.9
Unknown 3 10.7
Crohn’s distribution Ileocolonic 15 53.6
Ileal 6 21.4
Colonic isolated 6 21.4
UGI involvement 6 21.4
Perianal involvement 11 39.3
Crohn’s phenotype Inflammatory 16 57.1
Stricturing 7 25.0
Penetrating 5 17.9
Extraintestinal EIMs 8 28.6
manifestations No EIMs 20 71.4
UGI, upper gastrointestinal; EIM, extraintestinal manifestation; yr, years..
Table 2. Characteristics of orofacial granulomatosis.
N %
Timing of OFG diagnosis 
in relation to CD diagnosis






After CD diagnosis 18 64.3




CD not yet diag-
nosed
2 7.1




Associated symptoms Pain 25 89.3
Impaired speech or 
swallowing
6 21.4
Previous treatments for 
luminal CD
No medications 11 39.3
5-ASA only 2 7.1
IM +/- 5-ASA 5 17.9






CRP level Normal 10 35.7













Topical therapies 4 14.3
Steroid injections 2 7.1






Resistant to therapy 5 17.9
OFG, orofacial granulomatosis; CD, Crohn’s disease; 5-ASA, 
5-aminosalicylic acid; IM, immunomodulator; anti-TNF, anti-tumour ne-
crosis factor; EEN, exclusive enteral nutrition; VDZ, vedolizumab; UST, 
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these cases were followed up for ≥5 years and the other two were 
managed for 6  months and then discharged back to the referring 
physician. A single case had spontaneous remission without therapy 
[Table 2]. Follow-up occurred for an average of 5.32 years [range 
5–180 months].
A sub-analysis of the 12 patients who had histologically proven 
granulomatous disease included seven females and five males. with 
a mean age of 23.2 years [SD 11.9, range 13–60]. OFG was diag-
nosed prior to CD in two cases, concurrently in five, and after CD 
diagnosis in five. CD distribution was ileal in two, colonic in two, 
ileocolonic in seven, and isolated UGI in one. Perianal disease oc-
curred in five, UGI disease in two, and EIMs other than OFG in 
four. OFG distribution involved the lips in eight. Two cases were 
refractory to anti-TNFs, and 10 achieved remission [with steroids in 
three, EEN and AZA in one, infliximab in five, ustekinumab in 1].
4.  Discussion
This case series describes the clinical features and course of patients 
with CD + OFG. By the nature of this study, all those included had 
a diagnosis of CD, but it is important to note that OFG without 
CD is much more common: Campbell et al. looked at 207 patients 
with OFG, and 46 [22%] had intestinal CD.4 In similarity to other 
series, there is no gender predilection. The average age here is higher 
than previously reported, although five patients were included aged 
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Figure 1. Images from a 20 year-old female, diagnosed initially with OFG age 15 years, then pan-enteric Crohn’s 7 months later. Remission was achieved 
with mesalamine, azathioprine, and exclusive enteral nutrition. A] Cheilitis granulomatosa. B]. H&E staining [10x magnification] of lower lip biopsy showing 
infiltration of lymphocytes, plasmocytes, and non-caseating granuloma. C] Gastroscopy images showing patchy erythema in the gastric body and antrum. D] 
H&E staining [10x magnification] of pyloric antrum biopsy showing focal, chronic lymphocytic infiltration. E] H&E staining [2x magnification] of terminal ileum 
biopsy showing mild infiltration of lymphocytes and plasmocytes. F] H&E staining [10x magnification] of descending colon biopsy showing focal lymphocytosis, 
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with OFG in Campbell et al.’s study.4 Smoking is not associated, as 
most patients had never smoked. Few cases reported other EIMs, 
and the presence of EIMs was not associated with a treatment-
refractory disease course. There does appear to be a more severe 
intestinal disease, with high numbers with stricturing or penetrating 
disease and eight cases with previous intestinal resection. There was 
no predilection for OFG to occur with different locations of intes-
tinal Crohn’s, with a fair spread between small bowel, ileocolonic, 
and colonic disease. However, there was an over-representation of 
both UGI and perianal CD. Dupuy et al. have previously described 
the higher prevalence of UGI involvement in patients presenting with 
oral manifestations of CD.14 One study identified UGI involvement 
in 72 of 940 CD patients [7.6%],15 whereas our series identified six 
of 28 patients [21.4%]. Harty et al. had noted a higher incidence of 
concomitant perianal CD in those patients also presenting with oral 
disease.16 However, a limiting factor is that the numbers are small in 
these studies.
In this series, the diagnosis of OFG occurred in 64.3% at 
12 months to 33 years after the diagnosis of CD, whereas there were 
also eight cases of OFG diagnosed within a year of CD [28.6%] 
and two cases of OFG diagnosed prior to CD. This contrasts with 
Campbell et al.’s study where 42.5% [17/40] patients with OFG + CD 
developed OFG prior to CD [median 2 years, range 1–39], 20 devel-
oped OFG after CD [median 10 years, range 1–45], and three had 
OFG and CD diagnosed concurrently in the same year.4
Similar to previous reports, the patients in our series usually had 
multiple areas of the orofacial area affected, mostly involving the 
lips and buccal mucosa, as well as the tongue and gums commonly. 
Angular cheilitis and aphthous or deep ulcers were very common ac-
companying features, and other common associated symptoms were 
pain and impaired swallowing or speaking. This shows how disabling 
OFG can be and the need to address these problems separately. Only 
half the patients in our series had biopsy of their OFG lesion, with two 
out of these 10 having no granulomas detected. This may represent 
sampling error, as granulomas are often located deep within the oral 
mucosa, meaning shallow specimens can give false-negative results.17
The management of OFG can often be difficult, which is re-
flected in the 25% of patients resistant to anti-TNF based thera-
peutic regimens. Most patients require medical intervention, which 
can range from local treatments such as intralesional corticosteroid 
injections,18 systemic treatments for CD such as systemic cortico-
steroids and anti-TNF biologics,19 to rarer medications like the anti-
leprosy drug clofazimine and thalidomide.20 Elimination diets such 
as the cinnamon and benzoate-free diets have been successful in 
some patients.21,22 In this series, a variety of different treatment op-
tions led to remission. Notably, anti-TNF biologics led to remission 
in 32.1% of cases and there were also cases of both vedolizumab and 
ustekinumab [UST] leading to OFG remission. This appears to be the 
first reported case of VDZ leading to remission, and adds to the two 
recently published cases of UST inducing remission in OFG + CD.23,24 
This shows the importance of targeting the underlying intestinal CD 
in treating OFG. Interestingly, UST has also recently been shown to 
be useful for another extraintestinal granulomatous condition, meta-
static CD [MCD]: nine cases of MCD were treated with UST, and all 
responded with the first or second dose, with five achieving remis-
sion in a median time of 5 months.25 This may also have implications 
for the treatments of idiopathic OFG, particularly when therapeutic 
options appear to be exhausted.
The limitations of this study are that reporting is retrospective 
and histology was not available in all cases, although it is common 
for such diagnoses and assessment of response or remission to be 
made on clinical grounds. Patients included are from a select cohort, 
so caution must be exercised in comparing features with larger un-
selected cohorts in other studies. Furthermore, given the nature of a 
multicentre study of a rare condition, there was no standardisation 
of diagnosis or management.
To conclude, in this multicentre case series of selected patients 
with OFG + CD, the diagnosis of OFG mostly occurred after that 
of CD and can be many decades after, but may also occur before 
or concurrently with diagnosis of intestinal disease. Perianal disease 
and UGI disease were common associations, and there was a sig-
nificant symptom burden due to pain and impaired swallowing in 
many. Lastly, remission was obtained with a variety of treatments, 
including topical and intralesional agents, thalidomide, and different 
biologic agents, including VDZ and UST, although many remained 
resistant to multiple treatments.
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Figure 2: Bar chart showing number of cases with different areas of involvement by OFG. Note that there were 10 cases which had both lips and oral cavity 
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